CD33 and acute myeloid leukemia: Sun and colleagues conjugated liposomal daunorubicin with CD123/CD33 antibody by thiolation, and attained 1.8-fold higher cellular uptake and 1.53-fold (P < 0.001) greater cytotoxicity against acute myeloid leukemia (AML) cells [19].